Repository logo
 

Left atrial stiffness, exercise intolerance and injury biomarkers predict adverse outcomes in patients with heart failure with preserved ejection fraction

Accepted version
Peer-reviewed

Repository DOI


Change log

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex condition associated with high morbidity and mortality. This exploratory study aimed to assess the prognostic value of left atrial (LA) stiffness, exercise tolerance, and selected biomarkers in patients with HFpEF. We evaluated LA mechanics using 2D speckle tracking in 43 patients (mean age 77.2 years) from the OPTIMISE HFpEF study (NCT03617848). Biomarkers such as N-terminal pro brain-type natriuretic peptide, growth differentiation factor 15, and galectin-3 were measured. Patients also completed a six-minute walk test. Over a mean follow-up of 24.5 months, there were five deaths (11.4%) and 21 all-cause hospitalizations (48.8%). LA stiffness (HR 1.81; p=0.028) and N-terminal pro brain-type natriuretic peptide (HR 1.01; p=0.013) were independent mortality predictors. For hospitalizations, six-minute walk distance (HR 0.99; p=0.011) and growth differentiation factor 15 (HR 1.01; p=0.007) were significant independent predictors. This exploratory analysis indicates that LA stiffness, N-terminal pro brain-type natriuretic peptide, exercise intolerance, and growth differentiation factor 15 independently predict adverse events in HFpEF. Implementing a comprehensive therapeutic approach including lifestyle modifications, medical therapy, and, if necessary, more advanced interventions to improve LA mechanics, functional capacity and clinical biomarkers may improve outcomes for HFpEF patients.

Description

Keywords

Journal Title

NPJ Cardiovascular Health

Conference Name

Journal ISSN

Volume Title

Publisher

Publisher DOI

Publisher URL

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312).